WHAT IS CLAIMED IS:

1. Use of an antibody or antigen-binding fragment thereof that binds to human PD-1, in the manufacture of a medicament for the treatment of Merkel cell carcinoma in a human subject, wherein the antibody or antigen-binding fragment thereof comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and
the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and
the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).

2. Use of an antibody or antigen-binding fragment thereof that binds to human PD-1, in the manufacture of a medicament for the treatment of an endometrial cancer in a human subject, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and
the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and
wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and
the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).

3. The use of claim 2, wherein the endometrial cancer is microsatellite instability-high (MSI-H) endometrial cancer.

4. The use of claim 2, wherein the endometrial cancer is mismatch repair deficient (dMMR) endometrial cancer.

5. The use of claim 2, wherein the endometrial cancer is DNA polymerase ε (POLE) exonuclease domain mutation positive endometrial cancer.

6. Use of an antibody or antigen-binding fragment thereof that binds to human PD-1, in the manufacture of a medicament for the treatment of anal cancer in a human subject, wherein the antibody or antigen-binding fragment thereof comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and
the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and
the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).

7. The use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is to be administered at a dose of 1 mg/kg once every 2 weeks.

8. The use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is to be administered at a dose of 3 mg/kg once every 2 weeks.

9. The use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is to be administered at a dose of 3 mg/kg once every 4 weeks.

10. The use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is to be administered at a dose of 10 mg/kg once every 2 weeks.

11. The use of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment is to be administered at a dose of 10 mg/kg once every 4 weeks.

12. Use of an antibody or antigen-binding fragment thereof that binds to human PD-1, in the manufacture of a medicament for the treatment of a cancer in a human subject, wherein the antibody or antigen-binding fragment thereof comprises a VH domain comprising VH CDR1, VH CDR2, and VH CDR3, wherein:
the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7); and
the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8); and
wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10); and
the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11), and wherein the medicament is to be administered as a therapeutically effective fixed dose.

13. The use of claim 12, wherein the cancer is anal cancer, bladder cancer, breast cancer, colorectal cancer, endometrial cancer, hepatocellular carcinoma, glioma, kidney cancer, lung cancer, Merkel cell carcinoma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, rectal cancer, or sarcoma.

14. The use of claim 13, wherein the endometrial cancer is selected from the group consisting of microsatellite instability-high (MSI-H) endometrial cancer, mismatch repair deficient (dMMR) endometrial cancer, and DNA polymerase ε (POLE) exonuclease domain mutation positive endometrial cancer.

15. The use of any one of claims 1 to 14, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4.

16. The use of any one of claims 1 to 14, wherein the antibody comprises a heavy chain and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2.

17. The use of any one of claims 1 to 14, wherein the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5.

18. The use of any one of claims 1 to 14, wherein the antibody comprises a light chain and wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

19. The use of any one of claims 1 to 14, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5.

20. The use of any one of claims 1 to 14, wherein the antibody comprises a heavy chain and a light chain, and wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:2 and the light chain comprises the amino acid sequence set forth in SEQ ID NO:3.

21. The use of any one of claims 1 to 14, wherein the antibody is a humanized antibody.

22. The use of any one of claims 1 to 14, wherein the antigen-binding fragment is a single chain antibody, an Fab fragment, an F(ab')2 fragment, an Fab' fragment, an Fsc fragment, an Fv fragment, an scFv, an sc(Fv)2, or a diabody.

23. The use of any one of claims 1 to 22, wherein the antibody or antigen-binding fragment is to be administered intravenously.

24. The use of any one of claims 1, 2, 5, 6 or 12, wherein the antibody or antigen-binding fragment is to be administered at a dose of 375 mg once every 3 weeks

25. The use of any one of claims 1, 2, 5, 6 or 12, wherein the antibody or antigen-binding fragment is to be administered at a dose of 500 mg once every 4 weeks.

26. The use of any one of claims 1, 2, 5, 6 or 12, wherein the antibody or antigen-binding fragment is to be administered at a dose of 750 mg once every 4 weeks.